186 related articles for article (PubMed ID: 9155518)
41. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
43. Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families.
Montagna M; Santacatterina M; Torri A; Menin C; Zullato D; Chieco-Bianchi L; D'Andrea E
Oncogene; 1999 Jul; 18(28):4160-5. PubMed ID: 10435598
[TBL] [Abstract][Full Text] [Related]
44. Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
Anton A; Schott S; Kaip G; Rath M; Heil J; Aulmann S; Sinn HP
Arch Gynecol Obstet; 2014 May; 289(5):1079-85. PubMed ID: 24196303
[TBL] [Abstract][Full Text] [Related]
45. [Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance].
Shi H; You Z; Guo Y
Zhonghua Fu Chan Ke Za Zhi; 1998 Nov; 33(11):676-8. PubMed ID: 10806719
[TBL] [Abstract][Full Text] [Related]
46. [Hereditary ovarian cancer].
Zikán M; Foretová L; Cibula D; Kotlas J; Pohlreich P
Ceska Gynekol; 2006 May; 71(3):246-51. PubMed ID: 16768054
[TBL] [Abstract][Full Text] [Related]
47. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Santarosa M; Dolcetti R; Magri MD; Crivellari D; Tibiletti MG; Gallo A; Tumolo S; Della Puppa L; Furlan D; Boiocchi M; Viel A
Int J Cancer; 1999 Sep; 83(1):5-9. PubMed ID: 10449599
[TBL] [Abstract][Full Text] [Related]
48. Study of BRCA1 gene in hereditary breast and ovarian cancer.
Xiaoman D; Jinghe L
Chin Med Sci J; 1999 Dec; 14(4):195-9. PubMed ID: 12894890
[TBL] [Abstract][Full Text] [Related]
49. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
50. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.
Werness BA; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Dicioccio RA; Tsukada Y; Ponder BA; Piver MS
Hum Pathol; 2000 Nov; 31(11):1420-4. PubMed ID: 11112219
[TBL] [Abstract][Full Text] [Related]
51. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
52. Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features.
James PA; Sawyer S; Boyle S; Young MA; Kovalenko S; Doherty R; McKinley J; Alsop K; Beshay V; Harris M; Fox S; Lindeman GJ; Mitchell G
Fam Cancer; 2015 Jun; 14(2):287-95. PubMed ID: 25678442
[TBL] [Abstract][Full Text] [Related]
53. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson OT; Ranstam J; Borg A; Olsson H
J Clin Oncol; 1998 Feb; 16(2):397-404. PubMed ID: 9469321
[TBL] [Abstract][Full Text] [Related]
54. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
[TBL] [Abstract][Full Text] [Related]
55. [Management of hereditary ovarian cancer].
Joó JG; Ládi S; Nagy BZ; Langmár Z
Orv Hetil; 2011 Oct; 152(40):1596-608. PubMed ID: 21945869
[TBL] [Abstract][Full Text] [Related]
56. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
57. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
58. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
59. The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling.
Molyneux G; Smalley MJ
J Mammary Gland Biol Neoplasia; 2011 Apr; 16(1):51-5. PubMed ID: 21336547
[TBL] [Abstract][Full Text] [Related]
60. Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
Cortesi L; Turchetti D; Bertoni C; Zanocco-Marani T; Vinceti M; Silvestri C; Federico M; Silingardi V; Ferrari S
Eur J Hum Genet; 2003 Mar; 11(3):210-4. PubMed ID: 12673274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
